Shaanxi Panlong Pharmaceutical Group

What Shaanxi Panlong Pharmaceutical Group does

Shaanxi Panlong Pharmaceutical Group (陕西盘龙药业集团股份有限公司) is a publicly listed Chinese traditional Chinese medicine (TCM) manufacturer founded in 1997 and listed on the Shenzhen Stock Exchange A-share market (stock code 002864) since November 2017. The company is headquartered in Baqiao District, Xi'an, Shaanxi Province, with its main production base at the Panlong Ecological Industrial Park in Zhashui County, Shangluo. It operates a vertically integrated platform spanning GAP herb cultivation, pharmaceutical manufacturing across 23 GMP-certified production lines, R&D, sales, and pharmaceutical logistics, with 76 authorized patents (38 invention patents) and a brand value assessed at 14.82 billion RMB as of 2022.

The company's commercial product portfolio spans 12 therapeutic categories and over 100 product specifications, anchored by Panlong Qi Tablets (盘龙七片), a national exclusive proprietary patent medicine and Class A medical insurance product that is the leading TCM in China's musculoskeletal segment. Panlong Qi Tablets has been included in 11 national clinical guidelines, 4 expert consensus documents, 3 national textbooks, and 1 clinical pathway interpretation, with Level B evidence strength in the 2026 osteoarthritis guidelines. The company sells through a multi-channel model — direct hospital sales, retail pharmacy chains, and 500+ pharmaceutical commercial distributors — reaching 31 provinces, 4,000+ hospitals, and large pharmacy chains across China. It also produces OTC formulations, ultra-fine TCM powders, and consumer health products such as Glucosamine Sulfate Capsules (added to the 2025 National Reimbursement Drug Catalog) and Panlong Qi Children's Toothpaste.

The business model combines branded TCM product sales (one-time licensing of proprietary formulations), pharmaceutical distribution through the 51%-owned subsidiary Shaanxi Bohua Pharmaceutical (acquired 2020), and consumer health products. Revenue is generated across enterprise (hospital) and mid-market (retail pharmacy) channels, with field sales teams organized by province, KA accounts, and specialty drug segments. The company has signed a medical-care-retirement complex investment cooperation agreement, signaling exploration of healthcare services adjacent to the core pharmaceutical business. Management is founder-led (Chairman and General Manager Xie Xiaoling since 1997), with a deep mid-level operating team covering R&D, marketing, finance, and HR functions.

Name

Shaanxi Panlong Pharmaceutical Group

Legal name

陕西盘龙药业集团股份有限公司

Website

https://pljt.com

Company type

Public

Founded year

1997

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Shaanxi Panlong Pharmaceutical Group is a publicly listed Chinese TCM manufacturer whose flagship product, Panlong Qi Tablets, leads the musculoskeletal TCM segment and is sold across 31 provinces through 4,000+ hospitals, 500+ distributors, and major pharmacy chains.

Ownership category

akta.pro rank

Product category

Traditional Chinese Medicine Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Full-Line Pharmaceutical Wholesalers (HLAIAJAA)

Keywords

• Traditional Chinese medicine
• TCM pharmaceutical manufacturing
• Patent proprietary medicine
• Musculoskeletal TCM drugs
• GAP herb cultivation

Headquarters

HQ city

Baqiao

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of proprietary TCM products including Panlong Qi Tablets (盘龙七片) and other patent-protected medicines across 12 therapeutic categories. Products are sold through direct sales to hospitals and retail pharmacy channels across China.
2. Pharmaceutical Distribution: Pharmaceutical logistics and distribution services through subsidiary companies, including the acquisition of Shaanxi Bohua Pharmaceutical in 2020 to expand distribution network.
3. Health Products: Production and sale of health products and daily-use TCM preparations alongside pharmaceutical business.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Shaanxi Panlong Pharmaceutical Group manufactures and sells proprietary Traditional Chinese Medicine (TCM) pharmaceuticals, with the flagship product Panlong Qi Tablets (盘龙七片) leading China's musculoskeletal TCM market. The company is vertically integrated across GAP herb cultivation, drug production, R&D, sales, and pharmaceutical logistics, operating 23 GMP-certified production lines that produce over 100 product specifications spanning 12 therapeutic categories. Products are distributed to more than 4,000 hospitals and large pharmacy chains across 31 provinces of China through over 500 pharmaceutical commercial companies.

Product overview

Shaanxi Panlong Pharmaceutical Group is a modern high-tech pharmaceutical enterprise specializing in traditional Chinese medicine (TCM). The company operates a unified product platform with multiple therapeutic categories, with its core product being Panlong Seven Tablets (盘龙七片), a national proprietary patent medicine and medical insurance category A product. The product portfolio spans 12 functional categories including bone injury, cardiovascular, digestive, nourishing, respiratory, anti-inflammatory TCM, pediatric, gynecological, liver/gallbladder, and specialty medicine categories, offering over 100 product specifications. The company also produces ultra-fine powder TCM products and consumer health products like children's toothpaste. The business model combines pharmaceutical manufacturing, R&D, and sales with a distribution network covering 31 provinces across China, serving over 4,000 hospitals and major pharmacies.

Differentiator

Problem solved

Functional benefit

Brands

• 秦龙: 陕西好商标，2022年度获奖商标品牌
• 盘龙七片
• 盘龙七
• 盘龙久妹

Products and services

• Panlong Qi Tablets (盘龙七片) National proprietary patent medicine serving as the core product for musculoskeletal system rheumatism treatment. It has been included in multiple clinical diagnosis and treatment guidelines and is used for treating bone and joint diseases, osteoarthritis, rheumatoid arthritis, and osteoporosis. A leading medical insurance Category A product.
• Glucosamine Sulfate Capsules (硫酸氨基葡萄糖胶囊) OTC drug approved as a Class A OTC drug for bone and joint chronic disease management, included in the National Basic Medical Insurance Catalog (2025). It is managed as a non-prescription drug.
• Panlong Qi Children's Toothpaste (盘龙七儿童牙膏) Children's toothpaste product under the Panlong brand, marketed as a consumer health product and donated to local schools as part of social responsibility initiatives.
• Pharmaceutical Distribution Services Pharmaceutical wholesale and distribution services provided through majority-owned subsidiary Shaanxi Bohua Pharmaceutical Co., Ltd. (51% acquired in 2020), expanding the group's distribution network across China.

Quantifiable outcome

• Panlong Qi Tablets has been proven to improve clinical effectiveness rates, WOMAC scores, and VAS scores in osteoarthritis patients, with significant reduction in bone resorption markers and improvement in bone metabolism balance
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

17 partnerships are on record, tiered core and minor.

• Chinese Medicine Society Rheumatology Branch (中华中医药学会风湿病分会)coreStrategic or Co-development Partner · 11 March 2026Expert collaboration leading to Panlong Qi Tablets inclusion in national clinical guidelines with high-level evidence-based recommendation for osteoarthritis treatment.
• China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica (中国中医科学院中药研究所)coreStrategic or Co-development Partner · 11 March 2026Collaborative pharmacological research on Panlong Qi Tablets including mechanism of action studies and safety evaluation.
• Guang'anmen Hospital China Academy of Chinese Medical Sciences (中国中医科学院广安门医院)coreStrategic or Co-development Partner · 11 March 2026Randomized controlled trial (RCT) collaboration for knee osteoarthritis treatment with Panlong Qi Tablets.
• China Pharmaceutical University (中国药科大学)coreStrategic or Co-development Partner · 11 March 2026Collaborative real-world study and pharmacoeconomic evaluation for fracture treatment with Panlong Qi Tablets.
• Shaanxi Provincial Charity Association (陕西省慈善协会)coreGTM or Marketing Partner · 23 July 2024Disaster relief donations through the association, including 1 million RMB donation for flood relief in Shangluo region (Zhashui and Shanyang counties).
• Shaanxi Securities Regulatory Bureau (陕西证监局)coreGTM or Marketing Partner · 23 July 2024Collaboration on investor education and protection initiatives, including participation in the Shaanxi Investor Education Alliance.
• Shaanxi Securities Futures Association (陕西证券期货行业协会)minorGTM or Marketing Partner · 23 July 2024Joint education poverty alleviation donation program for students in Zhashui County.
• Shaanxi Listed Companies Association (陕西上市公司协会)coreGTM or Marketing Partner · 25 August 2023Joint education donation program for students from poor families admitted to universities, with combined donations of 270,000 RMB benefiting 82 students from Zhashui and Zhen'an middle schools.
• Xi'an Shangluo Chamber of Commerce (西安市商洛商会)minorGTM or Marketing Partner · 25 August 2023Joint participation in education donation programs supporting students from poor families in Shangluo region.
• Zhashui County Yingpan Town People's Government (柞水县营盘镇人民政府)coreStrategic or Co-development Partner · 22 July 2023Joint establishment of South Schisandra authentic herb planting and wild cultivation base, with planned standardized planting of 1,000 mu and wild cultivation of 100,000 mu. Panlong provides technical guidance for seedling cultivation, planting, maintenance, and processing.
• Zhashui County Health Bureau (柞水县卫健局)minorGTM or Marketing Partner · 27 June 2022Donation of 2 negative pressure ambulances to support local healthcare services, along with signing of Panlong Medical-Care-Retirement Complex investment cooperation agreement.
• Shaanxi Medical Chamber of Commerce (陕西省医药商会)minorStrategic or Co-development Partner · 27 June 2022Three-party cooperation with county government and local health bureau for medical-care-retirement complex project development.
• Securities Regulatory Bureau and Investment Education BasescoreGTM or Marketing Partner · 15 June 2022Joint investor education activities including 'Walk into Listed Company' and 'Shareholder is Coming' programs, collaborating with securities companies and investment education bases.
• Shaanxi Bohua Pharmaceutical Co., Ltd. (陕西博华医药有限公司)coreStrategic or Co-development Partner · 12 June 2020Acquisition of 51% equity in 2020 to expand pharmaceutical distribution business, completed with industrial and commercial change registration.
• China Medical Materials Association (中国医药物资协会)coreStrategic or Co-development Partner · 10 November 2019Active participation in poverty alleviation initiatives through the association, including 'Warm Tibet' charitable activities in collaboration with China Charity Federation.
• China Charity Federation (中华慈善总会)coreGTM or Marketing Partner · 10 November 2019Joint participation in poverty alleviation and charitable medical assistance programs, including the 'Warm Tibet' initiative.
• Shaanxi Normal University College of Life Sciences (陕西师范大学生命科学学院)minorStrategic or Co-development Partner · 18 March 2019Technical collaboration for honeysuckle planting projects in Xichuan Village, providing scientific guidance for herb cultivation.

Scale indicators9 records

Recent moves7 records

Expansion highlights14 records

Regional players

• Jointown Pharmaceutical Group: One of China's largest privately-owned pharmaceutical distributors, operating a nationwide pharma distribution and retail network. Comparable to Panlong's distribution arm (especially post-Bohua acquisition) and relevant given overlapping hospital and pharmacy channel coverage in China.

Emerging players

• Livzon Pharmaceutical Group: Diversified Chinese pharma group with both chemical drugs and TCM product lines, including specialties in digestive and women's health. Comparable in the TCM formulation segment and overlapping therapeutic categories (digestive, gynecological) with Panlong's broader portfolio.

Broad incumbents

• Shanghai Pharmaceuticals Holding: One of China's largest integrated pharmaceutical groups covering manufacturing, distribution, and retail pharmacy. Comparable given combined pharma manufacturing and distribution scale, and overlapping presence in drug distribution and TCM/chemical drug manufacturing that parallels Panlong's post-Bohua integrated model.
• Guangzhou Baiyunshan Pharmaceutical Holdings: Diversified Chinese pharmaceutical group combining TCM, Western medicine, and healthcare products with national distribution. Comparable as a multi-category Chinese pharma incumbent with hospital sales, OTC, and health-products channels overlapping with Panlong's portfolio.
• China Resources Sanjiu Medical & Pharmaceutical: Large state-owned TCM conglomerate with a broad OTC and prescription TCM portfolio spanning multiple therapeutic categories. Comparable as a national-scale branded TCM competitor with overlapping therapeutic categories (pediatric, gynecological, anti-inflammatory) and similar hospital/pharmacy distribution model.
• China Traditional Chinese Medicine Holdings: Hong Kong-listed subsidiary of Sinopharm focused on formulated TCMs with a broad product portfolio and strong hospital channel presence. Comparable as a leading TCM formulation company with overlapping distribution strategy through hospitals and pharmacies across China.
• Beijing Tongrentang: Iconic Chinese TCM brand with hundreds of years of heritage, operating both manufacturing and large retail pharmacy networks. Comparable as a flagship Chinese TCM brand with established brand value, multi-category portfolio, and nationwide distribution — though at much larger scale.

Direct peers

• Yunnan Baiyao Group: One of China's most prominent branded TCM pharmaceutical groups with a national distribution footprint and proprietary patented formulations. Highly comparable as a vertically integrated TCM manufacturer selling through hospital and pharmacy channels across multiple therapeutic categories.
• Shandong Dong-E E-Jiao: Specialty TCM manufacturer built around a flagship proprietary product (E-Jiao/ donkey-hide gelatin) with strong brand recognition and tonic/nourishing positioning. Comparable in business model as a single-flagship-anchored TCM company with category leadership and similar reliance on brand-driven consumer and OTC channels.
• Tibet Cheezheng Tibetan Medicine: Specialty TCM company focused on musculoskeletal and rheumatic conditions, with leading products in bone/joint pain relief. Closely comparable to Panlong given overlapping therapeutic focus (rheumatology/orthopedics), proprietary patent medicine positioning, and similar reliance on academic promotion in hospitals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shaanxi Panlong Pharmaceutical Group